A Pragmatic Trial of a Shared Decision-Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Study - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
A Practical Study on a Collaborative Decision-Making Approach to Enhance Medication Compliance and Health Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Investigation
Clinical Scorecard: A Practical Study on a Collaborative Decision-Making Approach to Enhance Medication Compliance and Health Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Investigation
At a Glance
Category
Detail
Condition
Systemic Lupus Erythematosus (SLE)
Key Mechanisms
Hydroxychloroquine (HCQ) prolongs disease-free and damage-free survival.
Target Population
Patients aged 18 years or older with a validated SLE diagnosis.
Care Setting
Rheumatology and lupus clinics
Key Highlights
83% of patients discontinue HCQ, leading to higher hospitalizations and mortality.
Shared decision-making (SDM) tools can reduce decisional conflicts and improve adherence.
Culturally appropriate e-versions of HCQ-SAFE were developed for English and Spanish speakers.
The study included patients with varying durations of HCQ use and aimed for diverse representation.
Guideline-Based Recommendations
Diagnosis
Validated SLE diagnosis according to the 2019 EULAR/American College of Rheumatology classification criteria.
Management
Use of HCQ as the cornerstone therapy for SLE.
Monitoring & Follow-up
Evaluate adherence and decisional conflicts using HCQ-SAFE tool.
Risks
Potential for macular toxicity associated with HCQ use.
Patient & Prescribing Data
Patients with SLE, including those reporting Spanish as their primary language.
Patients often face challenges in weighing benefits and harms of HCQ.
Clinical Best Practices
Implement shared decision-making tools in clinical practice.
Ensure culturally appropriate communication and materials for diverse patient populations.
by Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez-Giron, David Gazeley, Christie M. Bartels, Shivani Garg
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.
